Endothelial Regulatory Elements for Specific Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy methods struggle to achieve robust and specific expression of therapeutic genes in endothelial cells, often resulting in modest or non-specific expression levels and requiring high vector doses, which can be unsafe.
Innovation Solution
Development of endothelial cell-specific nucleic acid regulatory elements (EC-CREs) identified through a computational approach, enhancing transcription in endothelial cells by incorporating transcription factor binding site motifs, epigenetic signatures, and evolutionary conserved clusters, integrated into expression cassettes and vectors for targeted gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy methods are used, then gene delivery to endothelial cells can be achieved, but expression levels are modest and non-specific
Solution Approach 1:
The patent applies local quality by using endothelial cell-specific promoters and enhancers that are active only in endothelial cells, ensuring both specificity and high expression levels in the target tissue. The regulatory elements are designed to be tissue-specific, so the therapeutic gene is expressed highly only where needed.
Solution Approach 2:
The patent changes the regulatory parameters of gene expression by incorporating specific promoter sequences, enhancer elements, and chromatin opening motifs that are optimized for endothelial cells. This modifies the expression characteristics to achieve both high levels and specificity.
2Productivity
If high vector doses are used to achieve robust expression, then expression levels improve, but safety concerns arise
Solution Approach 1:
The patent changes the efficiency parameter of vector delivery by using optimized regulatory elements that dramatically improve transcriptional activity. This allows achieving robust expression at lower vector doses, reducing safety concerns associated with high doses.
Solution Approach 2:
The patent uses computational modeling and in silico analysis to identify and replicate successful regulatory element combinations that have been validated in endothelial cells, allowing efficient expression without requiring high vector doses.
3Productivity
If computational approach is used to identify regulatory elements, then expression efficiency improves, but development complexity increases
Solution Approach 1:
The patent performs preliminary computational identification and validation of regulatory elements before actual gene therapy application. This pre-characterization phase identifies the most effective elements, simplifying the overall development process despite the initial computational complexity.
Solution Approach 2:
The patent replaces traditional trial-and-error experimental approaches with computational modeling and in silico analysis to identify regulatory elements, reducing the need for extensive physical experimentation and simplifying the development workflow.
Data Source
AI summary
The disclosure provides nucleic acid regulatory elements that are able to enhance endothelial cell-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The nucleic acid regulatory elements, methods of employing these regulatory elements, uses of these elements, and expression cassettes and vectors containing these nucleic acid regulatory elements are particularly useful for applications using gene therapy, more particularly endothelial cell-directed gene therapy, and for vaccination purposes.